Cardiovascular and Renal Drugs Advisory Committee; Cancellation

---
identifier: "/us/fr/2012-20607"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Cardiovascular and Renal Drugs Advisory Committee; Cancellation"
title_number: 0
title_name: "Federal Register"
section_number: "2012-20607"
section_name: "Cardiovascular and Renal Drugs Advisory Committee; Cancellation"
positive_law: false
currency: "2012-08-22"
last_updated: "2012-08-22"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2012-20607"
document_type: "notice"
publication_date: "2012-08-22"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "77 FR 50702"
fr_volume: 77
docket_ids:
  - "Docket No. FDA-2012-N-0001"
fr_action: "Notice."
---


#  Cardiovascular and Renal Drugs Advisory Committee; Cancellation

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The meeting of the Cardiovascular and Renal Drugs Advisory Committee scheduled for September 14, 2012, is cancelled. The meeting is no longer needed. This meeting was announced in the *Federal Register* of July 23, 2012 (77 FR 43093).

**FOR FURTHER INFORMATION CONTACT:**

Kalyani Bhatt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, email: *[email protected],* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), to find out further information regarding FDA advisory committee information or visit our Web site at *http://www.fda.gov/AdvisoryCommittees/default.htm.*

Dated: August 17, 2012.

Jill Hartzler Warner,

Acting Associate Commissioner for Special Medical Programs.